Pfizer Breaks Ground for New State-of-Art Research Building
November 14, 2005
For Immediate Release
Contact: Ed Bryant
PFIZER BREAKS GROUND FOR NEW STATE-OF-THE-ART RESEARCH BUILDING
Nearly $200 Million Facility Will Further Pfizer’s Efforts To Discover, Develop New Medicines
[CHESTERFIELD, Mo., November 14, 2005] – Elected officials and other community leaders joined Pfizer research leaders today to break ground for the company's new nearly $200 million research building.
“The high-tech building that will rise here will further the efforts of our St. Louis colleagues to develop new medicines,” said John LaMattina, President of Pfizer Global Research and Development. “It will strengthen the role of St. Louis in Pfizer's global research enterprise.”
The nearly 330,000 square foot facility will provide Pfizer with space to relocate approximately 250 employees, currently dispersed throughout the St. Louis region, to its Chesterfield campus. It is scheduled to open in late 2008. The new facility will bring the total number of Pfizer employees located at the Chesterfield site to slightly over 1,000.
“Our goal for several years has been to create a unified and integrated research and development site that would bring all of our scientific work to a single location,” said Daniel P. Getman, Vice President and St. Louis Site Director. “This will strengthen our ability to deliver the new medicines.”
Globally, Pfizer researchers are working in hundreds of research projects across 18 therapeutic areas. Researchers in St. Louis, working closely with other Pfizer researchers around the globe, focus on potential medicines to treat cardiovascular disease, pain and inflammation, and Chronic Obstructive Pulmonary Disease (COPD) and respiratory diseases.
Pfizer Inc discovers, develops, manufactures and markets leading prescription medicines for humans and animals, and many of the world's best known consumer products.
# # #